Review findings

(2017) Preclinical behavioral study: unpredictable chronic mild stress (UCMS) in rats Rats, n≈6 per subgroup Intranasal Selank 300 µg/kg ± oral diazepam 1 mg/kg;

e You Might Also Like Related content you may find interesting Peptide Cognitive Semax Peptide Cognitive Dihexa Peptide Cognitive Pinealon Article guide FDA Peptide Categories Explained: Category 1 vs Category 2 (2026) Table of Contents What is Selank?

(review, 2013) Narrative review summarizing preclinical and limited clinical/domestic data N/A (review of animal and Russian clinical reports) Describes Selank 0.15% nasal drops; summarizes preclinical dosing paradigms Claims of registration/medical use in Russia; preclinical endpoints: behavior, monoamines, gene expression, BDNF, enkephalin metabolism Notes Russian registration of Selank nasal formulation; reports anxiolytic/neuroprotective preclinical signals and gene‑expression/BDNF/enkephalin ...

e You Might Also Like Related content you may find interesting Peptide Cognitive Semax Peptide Cognitive Dihexa Peptide Cognitive Pinealon Article guide FDA Peptide Categories Explained: Category 1 vs Category 2 (2026) Table of Contents What is Selank?

Preclinical and mechanistic evidence • Behavioral models: In rodents, Selank shows anxiolytic-like activity and can enhance diazepam’s effect in an unpredictable chronic mild stress model, with the combination restoring anxiety measures to pre-stress values.

Regulatory status and registration A narrative review states the Selank 0.15% nasal formulation “was registered by the Russian Federation Ministry of Health and approved for medical use.” Independent verification within major international regulators or registries was not identified in our searches.

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 14 min read Peptide Stacking Guide 2026: Best Combinations by Goal The definitive 2026 guide to peptide stacking organized by goal.

200-400 mcg per dose subcutaneous Frequency 2-3 times daily (intranasal); once daily (SC, 5 days per week) Duration 30 days on, 30 days off; approximately 6 cycles per year 💊 Administration Route Intranasal Schedule 2-3 times daily (intranasal); once daily (SC, 5 days per week) Timing Morning and early afternoon doses; avoid late evening due to potential activating effects ✓ Rotate injection sites 📅 Cycle Duration 30 days on, 30 days off; approximately 6 cycles per year Repeatable Yes Course-based protocol with rest periods Preparation & Storage ✓ Ready-to-use — no reconstitution required ⚗️ Suggested Bloodwork ( 5 tests) CBC with differential When: Baseline Why: Selank has immunomodulatory properties; baseline immune status CMP When: Baseline Why: Liver and kidney function baseline Thyroid panel When: Baseline Why: Rule out thyroid dysfunction as cause of anxiety/cognitive issues Cortisol (AM) When: Baseline Why: Baseline HPA axis assessment;

The current evidence base for Selank consists primarily of preclinical studies and a small, uncontrolled human report.

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 14 min read Peptide Stacking Guide 2026: Best Combinations by Goal The definitive 2026 guide to peptide stacking organized by goal.

100 μg/kg daily Wound repair: histological regeneration, reduced necrosis Accelerated granulation and epithelization, earlier scab rejection and partial defect closure vs control Suggests systemic reparative benefits in tissue injury models Lyapina 2006 In vitro/animal coagulation assays Comparative pharmacology of proline‑containing oligopeptides Various peptides including Selank (experimental concentrations) Effects on anticoagulant activity / hemostasis parameters Demonstrated specificity of anticoagulant effects among glyprolines, Semax , and Selank (differential activity reported) Identifies peripheral hemostatic actions warranting safety evaluation Kolomin 2013 (review) Mixed preclinical and clinical data Narrative review summarizing gene‑expression and clinical responses Clinical reports reference 0.15% formulation ≈2700 μg/day intranasal Gene expression modulation; clinical rapid vs slow responder patterns Bcl6 mRNA: ~4.0× (6 h) and ~8.3× (24 h) after Selank; clinical ~40% rapid responders vs ~60% gradual Integrates transcriptomic changes with observed clinical response heterogeneity Preclinical Evidence # Overview and scope Selank (TP-7;

Searches did not yield NCT-registered interventional trials of Selank. • Uncontrolled study (conference abstract): A small intranasal study in adults with DSM-IV generalized anxiety disorder (n=20) reported two response profiles: approximately 40% “rapid responders” (HARS reduction by Day 3) and 60% “conventional responders” (improvement by Day 14).

Selank: Anxiolytic Nootropic Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Restore access No thanks, continue reading Related Reading Peptide Semax ACTH-derived neuroprotective peptide Peptide Pinealon neuroprotective bioregulatory tripeptide Peptide Oxytocin peptide How Selank works at the cellular level Overview of Selank benefits and applications Scientific Details Molecular Formula C33H57N11O9 Molecular Weight 751.9 Da CAS Number 129954-34-3 Sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro What is Selank? # Selank is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Restore access No thanks, continue reading Related Reading Peptide Semax ACTH-derived neuroprotective peptide Peptide Pinealon neuroprotective bioregulatory tripeptide Peptide Oxytocin peptide How Selank works at the cellular level Overview of Selank benefits and applications Scientific Details Molecular Formula C33H57N11O9 Molecular Weight 751.9 Da CAS Number 129954-34-3 Sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro What is Selank? # Selank is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Peptide Protocol Wiki February 28, 2026 Ipamorelin Retatrutide Tesamorelin + 12 more Guide 11 min read How to Choose Your First Peptide: A Decision Framework by Goal A comprehensive decision framework to help beginners identify the right peptide for their goals.

ic binding sites in cortical tissue without changing affinity, and gene-expression changes after Selank show a positive correlation with those induced by exogenous GABA.

Opioid signaling via preserved enkephalins: By inhibiting enkephalinases, Selank elevates endogenous enkephalin tone, activating Gi/o-coupled opioid receptors and impacting cAMP, ERK/MAPK, and AKT pathways that contribute to anxiolysis and stress resilience (inference consistent with observed pharmacology).

uropilin‑1 and can signal via VEGF/TGF-β–related axes; however, there is no direct biochemical evidence that Selank itself binds neuropilin‑1.

Biochemical inhibition of serum enkephalinases by Selank and active fragments; behavioral naloxone sensitivity and opioid-system involvement reported Increased endogenous enkephalins → activation of opioid receptor signaling (Gi/o) → downstream modulation of cAMP, MAPK/Akt pathways (proposed, inf...

Increased neurotrophic support → neuroprotective, pro-plasticity effects; may reverse stress-induced deficits Direct TrkB agonism not shown; effects reported at expression level (mRNA/protein), causal linkage inferred Ion homeostasis & neurotransmitter transporters (SLCs) NCX3 (SLC8A3), glutamate transporter EAAT2 (SLC1A2), choline transporter (SLC5A7), proline transporter (SLC6A20) Transcriptomic profiling after Selank (single/curative dosing) shows up/down regulation of SLC8A3, SLC1A2, SLC5A7, SLC6A20 and other ion/neurotrans...

ulation (cytokines / chemokines) Multiple cytokine/chemokine genes and receptors (spleen transcriptome changes) Selank and fragments changed expression of many chemokine/cytokine genes in spleen (6–24 h post‑injection); shifts consistent with Th1/Th2 balance ...

t disorder) Generalized anxiety disorder (GAD): In a clinical study of 20 adults receiving intranasal Selank 2700 μg/day, two response patterns were observed.

Peptide Protocol Wiki February 28, 2026 Ipamorelin Retatrutide Tesamorelin + 12 more Guide 11 min read How to Choose Your First Peptide: A Decision Framework by Goal A comprehensive decision framework to help beginners identify the right peptide for their goals.

Report an Error Compare Selank with Other Peptides Selank vs Semax Selank for anxiety reduction and stress resilience with immunomodulatory benefits;

Stress resilience and interaction with benzodiazepines (preclinical) In rats exposed to unpredictable chronic mild stress (UCMS), Selank (300 μg/kg intranasal, 14 days) reduced anxiety‑like behavior, and the Selank+diazepam combination was most effective: compared with UCMS+saline, open‑arm time increased 8.9‑fold and closed‑arm time decreased 2‑fold;

Selank doses Pre-filled reconstitution and dose math for Selank New to peptides?

ank Is Selank approved anywhere?

DOI: 10.4236/nm.2013.44032): The study demonstrated of GAD patients showed rapid response by day 3 of 40% Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo , published in Doklady Biological Sciences (Inozemtseva LS et al., 2008;

Key study details are tabulated here for reference: Study (first author, year) Model / Population Design & Comparator Selank Dose / Route Primary Outcomes Quantitative Results Notes Syunyakov 2012 Adults with GAD (n=20) Clinical trial (no placebo reported) Intranasal 2700 μg/day; single 900 μg for EEG Anxiety (HARS) and pharmaco‑EEG changes Rapid responders (40%): HARS 20.3 → 7.0 by Day 3; conventional responders: 16.1 → 6.2 by Day 14;

ed) Reported intranasal Selank dosing regimens (e.g., 0.15% formulation; examples of daily µg dosing) Reported rapid and gradual clinical response patterns; mood, sleep, autonomic symptom improvements described Documents real‑world/domestic usage patterns and claimed clinical responses supporting prior small studies Often non‑peer‑reviewed or limited transparency about methods/outcomes; lacks randomized controlled data and standardized adverse‑event reporting Dorofeeva et al.

Clinical reports reference 0.15% formulation ≈2700 μg/day intranasal Anxiolytic efficacy, enkephalin modulation, enkephalinase inhibition Selank reported comparable anxiolysis to medazepam; increased serum Leu‑enkephalin and inhibition of enkephalin‑degrading enzymes (in vitro IC effe...

(2019, JLCR) Mechanistic radioligand / molecular pharmacology (preclinical) Rodent tissue/ligand binding preparations Radioligand binding assays with Semax/Selank models; [3H]ACh and [3H]GABA used as probes Changes in specific binding of [3H]GABA and [3H]ACh; delayed effects on receptor‑binding sites after stress models Demonstrates that Semax/Selank can modulate specific binding of GABAergic and cholinergic probes, consistent with allosteric/modulatory effects on ...

ls Indicates immunocorrective effects under stress (supports neuroimmune role) Azhikova 2020 Rats with thermal burn wounds Experimental burn model; systemic peptide treatment vs untreated Selank i.p.

200-400 mcg per dose subcutaneous Frequency 2-3 times daily (intranasal); once daily (SC, 5 days per week) Duration 30 days on, 30 days off; approximately 6 cycles per year 💊 Administration Route Intranasal Schedule 2-3 times daily (intranasal); once daily (SC, 5 days per week) Timing Morning and early afternoon doses; avoid late evening due to potential activating effects ✓ Rotate injection sites 📅 Cycle Duration 30 days on, 30 days off; approximately 6 cycles per year Repeatable Yes Course-based protocol with rest periods Preparation & Storage ✓ Ready-to-use — no reconstitution required ⚗️ Suggested Bloodwork ( 5 tests) CBC with differential When: Baseline Why: Selank has immunomodulatory properties; baseline immune status CMP When: Baseline Why: Liver and kidney function baseline Thyroid panel When: Baseline Why: Rule out thyroid dysfunction as cause of anxiety/cognitive issues Cortisol (AM) When: Baseline Why: Baseline HPA axis assessment;

dose: 400 mcg · cycle: 30 days on · route: subcutaneous · timing: Morning · frequency: daily · reconstitution: reconstitution

100 μg/kg daily Wound repair: histological regeneration, reduced necrosis Accelerated granulation and epithelization, earlier scab rejection and partial defect closure vs control Suggests systemic reparative benefits in tissue injury models Lyapina 2006 In vitro/animal coagulation assays Comparative pharmacology of proline‑containing oligopeptides Various peptides including Selank (experimental concentrations) Effects on anticoagulant activity / hemostasis parameters Demonstrated specificity of anticoagulant effects among glyprolines, Semax , and Selank (differential activity reported) Identifies peripheral hemostatic actions warranting safety evaluation Kolomin 2013 (review) Mixed preclinical and clinical data Narrative review summarizing gene‑expression and clinical responses Clinical reports reference 0.15% formulation ≈2700 μg/day intranasal Gene expression modulation; clinical rapid vs slow responder patterns Bcl6 mRNA: ~4.0× (6 h) and ~8.3× (24 h) after Selank; clinical ~40% rapid responders vs ~60% gradual Integrates transcriptomic changes with observed clinical response heterogeneity Preclinical Evidence # Overview and scope Selank (TP-7;

dose: 100 μg · route: intranasal · frequency: daily

(2016) Preclinical gene‑expression study (rats); intranasal dosing Rats (group sizes pooled; exact n not clearly detailed) Single intranasal Selank 300 µg/kg vs GABA; frontal cortex harvested 1 h and 3 h Expression of 84 neurotransmission‑related genes (qPCR panel) Selank altered expression of many GABAergic/neurotransmission genes (45 genes at 1 h;

dose: 300 µg · route: intranasal

(2017) Preclinical behavioral study: unpredictable chronic mild stress (UCMS) in rats Rats, n≈6 per subgroup Intranasal Selank 300 µg/kg ± oral diazepam 1 mg/kg;

dose: 300 µg · route: Intranasal

Key study details are tabulated here for reference: Study (first author, year) Model / Population Design & Comparator Selank Dose / Route Primary Outcomes Quantitative Results Notes Syunyakov 2012 Adults with GAD (n=20) Clinical trial (no placebo reported) Intranasal 2700 μg/day; single 900 μg for EEG Anxiety (HARS) and pharmaco‑EEG changes Rapid responders (40%): HARS 20.3 → 7.0 by Day 3; conventional responders: 16.1 → 6.2 by Day 14;

dose: 2700 μg · route: Intranasal

Clinical reports reference 0.15% formulation ≈2700 μg/day intranasal Anxiolytic efficacy, enkephalin modulation, enkephalinase inhibition Selank reported comparable anxiolysis to medazepam; increased serum Leu‑enkephalin and inhibition of enkephalin‑degrading enzymes (in vitro IC effe...

dose: 2700 μg · route: intranasal

Tissue repair model: In rats with thermal burns, systemic Selank (100 μg/kg daily, i.p.) accelerated reparative regeneration, with earlier granulation/epithelization, earlier scab rejection, and partial wound closure, compared with untreated animals (histological endpoints).

dose: 100 μg · frequency: daily

Stress resilience and interaction with benzodiazepines (preclinical) In rats exposed to unpredictable chronic mild stress (UCMS), Selank (300 μg/kg intranasal, 14 days) reduced anxiety‑like behavior, and the Selank+diazepam combination was most effective: compared with UCMS+saline, open‑arm time increased 8.9‑fold and closed‑arm time decreased 2‑fold;

dose: 300 μg · route: intranasal

t disorder) Generalized anxiety disorder (GAD): In a clinical study of 20 adults receiving intranasal Selank 2700 μg/day, two response patterns were observed.

dose: 2700 μg · route: intranasal

Anxiolytic and nootropic peptide for anxiety reduction and cognitive enhancement 💉 Dosing Amount 300-600 mcg per dose intranasal;

dose: 600 mcg · route: intranasal

DZ 1 mg/kg oral;

dose: 1 mg · route: oral

EPM behavioral assay Selank intranasal 300 μg/kg;

dose: 300 μg · route: intranasal

A single 900 μg dose produced pharmaco‑EEG changes (↑beta, ↓theta/low‑alpha; p 0.05).

dose: 900 μg

Acute pharmaco-EEG after a single 900 µg dose showed increased beta and decreased theta/low alpha in rapid responders.

dose: 900 µg

elank 0.15% ~2700 µg/day (single 900 µg for EEG) Hamilton Anxiety Rating Scale (HARS); acute EEG changes 40% 'rapid' responders (large HARS drop by Day 3); remaining 60% improved by Day 14; single‑dose EEG: ↑beta, ↓theta/low‑alpha in rapid responders (...

dose: 2700 µg

Selank+DZ vs saline: open‑arm time ↑8.9×, closed‑arm time ↓2× Shows Selank alone and synergistic potentiation of DZ under chronic stress Kozlovskaya 2003 Rats in stress/novelty paradigms Preclinical behavioral study vs controls and tuftsin fragments Reported standard dose 300 μg/kg (route per study) Adaptive behavior, exploratory and anti‑anxiety effects Peripheral activity +63.4%; vertical activity +10.2%; hole investigations +23.0% Early preclinical evidence of nootropic/activating plus anxiolytic profile Yasenyavskaya 2022 (immunomodulation) Rodent “social” stress model Experimental stress model; immunological assays (DTH, DAT, phagocytosis) Single/acute injections (doses per study) Restoration of cellular/humoral immunity and phagocytic function Selank restored DTH, DAT responses and neutrophil phagocytic activity versus stressed contro

dose: 300 μg

Earlier work in stress/novelty paradigms reported Selank (≈300 μg/kg) increased peripheral activity (+63.4%), vertical activity (+10.2%), and exploratory hole‑poking (+23.0%), and improved escape behavior—consistent with anti‑anxiety and pro‑adaptive effects.

dose: 300 μg

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

Selank: Anxiolytic Nootropic Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Selank 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Selank Cognitive Enhancement Immune Support approved Selank Also known as: TP-7, Selanc, Thr-Lys-Pro-Arg-Pro-Gly-Pro Compare with 1 peptide Research compiled by Peptide Protocol Wiki 📅 Updated February 1, 2026 Citations Verified TL;DR Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence for enhanced stability.

Browse all cognitive peptides → Table of Contents 📌 TL;DR • Approved as an anxiolytic in Russia (intranasal formulation) • Demonstrates anxiolytic effects without sedation or dependence in studies • Modulates BDNF expression and monoamine neurotransmitter systems • Retains immunomodulatory properties from parent compound tuftsin Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference

Overall, the evidence quality for efficacy in anxiety disorders is low, with substantial gaps and risk of bias.

s “without” typical benzodiazepine adverse effects, but this is not substantiated by robust controlled human datasets.

tcomes. • Mechanism incompletely defined in humans: While GABAergic, enkephalin, monoaminergic, BDNF, and neuroimmune pathways are implicated in animals, confirmation in humans is lacking. • Safety data sparse: Absence of systematic adverse event collection and long-term safety surveillance in controlled clinical settings. • Generalizability and bias risk: Small samples, strain- and dose-dependence in animals, potential conflicts of interest, and quality concerns for some journals limit confidence and generalizability.

Very small uncontrolled sample; conference abstract with limited methods, no blinding/placebo, short follow‑up, sparse safety/adverse‑event reporting Kolomin et al.

ed) Reported intranasal Selank dosing regimens (e.g., 0.15% formulation; examples of daily µg dosing) Reported rapid and gradual clinical response patterns; mood, sleep, autonomic symptom improvements described Documents real‑world/domestic usage patterns and claimed clinical responses supporting prior small studies Often non‑peer‑reviewed or limited transparency about methods/outcomes; lacks randomized controlled data and standardized adverse‑event reporting Dorofeeva et al.

PMID: 26924987): The study showed selank altered expression of 45 neurotransmission genes in rat frontal cortex at 1 hour, with changes overlapping GABA induced transcriptional signatures Related Reading # Selank research studies and evidence Selank dosing protocols Selank side effects profile Cerebrolysin research guide Nemifitide research guide Stay current on Selank research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Accordingly, the certainty about human safety and adverse events is low.

Selank modulates stress response CBC When: End of 30-day cycle Why: Monitor immunomodulatory effects 💡 Key Considerations → Contraindication: Limited safety data outside Russian regulatory framework; caution in pregnancy and lactation; avoid in patients with bleeding disorders (tuftsin analog may affect immune/coagulation parameters) Subscribe to unlock this

The abstract lacks a control group, randomization, blinding, detailed safety reporting, and longer follow-up, substantially limiting inference. • Domestic clinical use reports: A narrative review describes clinical use and claims Russian registration of a 0.15% intranasal formul

Key limitations, evidence gaps, and criticisms • Lack of robust human RCTs: No randomized, blinded, placebo-controlled trials with transparent protocols, prespecified endpoints, and adequate sample sizes are evident in major registries or the accessible literature. • Small, uncontrolled clinical signals: The only accessible human study is a small, uncontrolled conference abstract with short follow-up and limited safety reporting, precluding causal inference. • Reliance on preclinical and domestic literature: Much of the evidence comes from developer-affiliated groups and domestic sources, with limited independent, international replication and several methodological constraints. • Surrogate and mechanistic endpoints: Heavy emphasis on acute gene-expression changes, binding studies, and EEG correlates rather than durable, clinically meaningful ou

Rigorous, preregistered, placebo-controlled RCTs with standardized outcomes and safety monitoring are needed before strong clinical claims can be substantiated.

Selank modulates stress response CBC When: End of 30-day cycle Why: Monitor immunomodulatory effects 💡 Key Considerations → Contraindication: Limited safety data outside Russian regulatory framework; caution in pregnancy and lactation; avoid in patients with bleeding disorders (tuftsin analog may affect immune/coagulation parameters) Subscribe to unlock this

Report an Error Compare Selank with Other Peptides Selank vs Semax Selank for anxiety reduction and stress resilience with immunomodulatory benefits;

Restore access No thanks, continue reading Related Reading Peptide Semax ACTH-derived neuroprotective peptide Peptide Pinealon neuroprotective bioregulatory tripeptide Peptide Oxytocin peptide How Selank works at the cellular level Overview of Selank benefits and applications Scientific Details Molecular Formula C33H57N11O9 Molecular Weight 751.9 Da CAS Number 129954-34-3 Sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro What is Selank? # Selank is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

100 μg/kg daily Wound repair: histological regeneration, reduced necrosis Accelerated granulation and epithelization, earlier scab rejection and partial defect closure vs control Suggests systemic reparative benefits in tissue injury models Lyapina 2006 In vitro/animal coagulation assays Comparative pharmacology of proline‑containing oligopeptides Various peptides including Selank (experimental concentrations) Effects on anticoagulant activity / hemostasis parameters Demonstrated specificity of anticoagulant effects among glyprolines, Semax , and Selank (differential activity reported) Identifies peripheral hemostatic actions warranting safety evaluation Kolomin 2013 (review) Mixed preclinical and clinical data Narrative review summarizing gene‑expression and clinical responses Clinical reports reference 0.15% formulation ≈2700 μg/day intranasal Gene expression modulation; clinical rapid vs slow responder patterns Bcl6 mRNA: ~4.0× (6 h) and ~8.3× (24 h) after Selank; clinical ~40% rapid responders vs ~60% gradual Integrates transcriptomic changes with observed clinical response heterogeneity Preclinical Evidence # Overview and scope Selank (TP-7;

(2019, JLCR) Mechanistic radioligand / molecular pharmacology (preclinical) Rodent tissue/ligand binding preparations Radioligand binding assays with Semax/Selank models; [3H]ACh and [3H]GABA used as probes Changes in specific binding of [3H]GABA and [3H]ACh; delayed effects on receptor‑binding sites after stress models Demonstrates that Semax/Selank can modulate specific binding of GABAergic and cholinergic probes, consistent with allosteric/modulatory effects on ...

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 14 min read Peptide Stacking Guide 2026: Best Combinations by Goal The definitive 2026 guide to peptide stacking organized by goal.

Peptide Protocol Wiki March 7, 2026 BPC-157 TB-500 AOD-9604 + 11 more Guide 18 min read Most Popular Therapeutic Peptides in 2026: 15 Ranked by Research Interest The 15 most popular therapeutic peptides in 2026, ranked by clinical trial activity, search interest, and research community adoption.

Peptide Protocol Wiki February 28, 2026 Ipamorelin Retatrutide Tesamorelin + 12 more Guide 11 min read How to Choose Your First Peptide: A Decision Framework by Goal A comprehensive decision framework to help beginners identify the right peptide for their goals.

e You Might Also Like Related content you may find interesting Peptide Cognitive Semax Peptide Cognitive Dihexa Peptide Cognitive Pinealon Article guide FDA Peptide Categories Explained: Category 1 vs Category 2 (2026) Table of Contents What is Selank?

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 mor